中国肺癌杂志2025，Vol.28Issue(11)：866-874,9.DOI:10.3779/j.issn.1009-3419.2025.102.42
放疗联合免疫治疗在不可切除Ⅲ期非小细胞肺癌中的临床研究进展及未来展望
Combination of Radiotherapy and Immunotherapy for Unresectable Stage Ⅲ Non-small Cell Lung Cancer:Clinical Progress Advances and Future Directions
摘要
Abstract
Stage Ⅲ non-small cell lung cancer(NSCLC)accounts for approximately 30%of newly diagnosed NSCLC cases,and the vast majority of these patients present with unresectable disease.Its unresectable nature makes definitive chemoradiotherapy the cornerstone of treatment.In recent years,with immune checkpoint inhibitors(ICIs)be-coming a major research focus in lung cancer,increasing evidence demonstrates that the combination of radiotherapy and immunotherapy(iRT)can significantly enhance antitumor efficacy through synergistic mechanisms.The groundbreaking results of the landmark PACIFIC trial further established consolidation immunotherapy following concurrent chemoradio-therapy as the standard of care.However,controversies persist regarding optimal radiotherapy strategies,timing of immune intervention,management of adverse reactions,and exploration of biomarkers.This review aims to systematically elucidate the synergistic mechanisms of iRT,summarize clinical trial advances under different iRT treatment modalities(concurrent,consolidation and induction),and provide an in-depth analysis of key issues in current clinical practice along with future research directions.关键词
肺肿瘤/放疗/免疫治疗/免疫检查点抑制剂/生物标志物Key words
Lung neoplasms/Radiotherapy/Immunotherapy/Immune checkpoint inhibitors/Biomarkers引用本文复制引用
谭左源,钟雨玲,王婧怡,邬麟..放疗联合免疫治疗在不可切除Ⅲ期非小细胞肺癌中的临床研究进展及未来展望[J].中国肺癌杂志,2025,28(11):866-874,9.基金项目
This paper was supported by the grants from National Key Clinical Specialty Scientific Research Project(No.Z2023098),Hunan Provincial Health High-level Talent Scientific Research Project(No.R2023125),Science and Technology Innovation Program of Hunan Province(No.2023SK4024)and Hunan Cancer Hospital Climb Plan(No.ZX2020005-5)(All to Lin WU). 本文受国家重点临床专科科研专项项目(No.Z2023098)、湖南省卫生健康高层次人才重大科研专项(No.R2023125)、湖南省科技创新计划(No.2023SK4024)及湖南省肿瘤医院"科研攀登计划"(No.ZX2020005-5)资助 （No.Z2023098）
